CPGs define the use of diagnostic, therapeutic and preventive modalities, including non-invasive and invasive procedures, in the management of patients with various liver diseases. They are intended to assist physicians and other healthcare providers as well as patients and interested individuals in the clinical decision making process by describing a range of generally accepted approaches for the diagnosis, treatment and prevention of specific liver diseases. CPGs have to be distinguished from consensus statements and position papers.
Future guidelines include:
 |
EASL is pleased to announce the publication of its 4th Clinical Practice Guidelines on "The Management of Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome in Cirrhosis". 
|
 |
EASL is pleased to announce the publication of its 3rd Clinical Practice Guidelines on the Management of HFE Hemochromatosis (HFE-HC).
|
 |
In October 2008, EASL proudly published its first CPG on the "Management of Chronic Hepatitis B", eight months later new subject matter was published in the same series of Clinical Practice Guidelines, this time on the Management of Cholestatic Liver Diseases.
|
 |
Worldwide, hepatitis B virus is a major cause of liver disease (acute and chronic hepatitis, cirrhosis and liver cancer). Approximately, 350 million individuals are infected.
|
